Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets
CDRB436G2401
Approved small_molecule active
Quick answer
Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets for Children and Adolescents with Cancers Harboring V600 mutation. is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Children and Adolescents with Cancers Harboring V600 mutation.
- Phase
- Approved
- Modality
- small_molecule
- Status
- active